Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2

מצבים רפואיים

Myelofibrosis (PMF) · Post Essential Thrombocythemia Myelofibrosis (ET-MF) · Post Polycythemia Vera Related Myelofibrosis (PV-MF)

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Moffitt Cancer Center, Tampa, Florida, United States

    Contact: Principal Investigator (Andrew Kuykendall, MD)
  • Emory University, Atlanta, Georgia, United States

    Contact: Principal Investigator (Anthony Hunter, MD)
  • Roswell Park Cancer Institute, Buffalo, New York, United States

    Contact: Principal Investigator (Eunice Wang, MD)
  • Ruttenberg Treatment Center, New York, New York, United States

    Contact: Principal Investigator (Marina Kremyanskaya)
  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Principal Investigator (Brian Chernak, MD)
  • NewYork-Presbyterian/Weill Cornell Medical Center, New York, New York, United States

    Contact: Principal Investigator (Ghaith Abu-Zeinah, MD)
  • Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

    Contact: Principal Investigator (Rupali Bhave, MD)
  • The Cleveland Clinic Foundation, Cleveland, Ohio, United States

    Contact: Principal Investigator (Aaron Gerds, MD)
  • The Ohio State University, Columbus, Ohio, United States

    Contact: Principal Investigator (Shivani Handa, MD)
מובילי המחקר
  • Marina Kremyanskaya, PhD, MD

    Study Chair

    Icahn School of Medicine at Mount Sinai

  • Aaron Gerds, MD, MS

    Study Chair

    Cleveland Clinic Taussig Cancer Institute